Nick McFarland, MD

Nick McFarland, MD, PhD

(352) 274-5400

Request an Appointment

Publications

The Er Retention Protein Rer1 Promotes Alpha-Synuclein Degradation Via the Proteasome
PLoS One
2017

Progression Marker of Parkinson's Disease: a 4-Year Multi-Site Imaging Study
Brain
2017

Functional Activity of the Sensorimotor Cortex and Cerebellum Relates to Cervical Dystonia Symptoms
Human brain mapping
2017

Depressive Symptoms Are Frequent in Atypical Parkinsonian Disorders
Movement Disorders Clinical Practice
2017

Weight Loss and Impact On Quality of Life in Parkinson's Disease
PLoS One
2015

Unexpected dual task benefits on cycling in Parkinson disease and healthy adults: a neuro-behavioral model.
PloS one
2015

Global Attentional Neglect of Segmented Lines in Parkinson's Disease
Neurocase
2015

Distinct Functional and Macrostructural Brain Changes in Parkinson's Disease and Multiple System Atrophy
Human brain mapping
2015

Abnormal Tactile Pressure Perception in Parkinson's Disease
Journal of Clinical and Experimental Neuropsychology
2015

The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry
The American Journal Of Geriatric Psychiatry
2014

The 'Brittle Responseandquot; To Parkinson's Disease Medications: Characterization and Response To Deep Brain Stimulation
PLoS One
2014

MRI reveals brain abnormalities in drug-naive Parkinson's disease.
Exercise and sport sciences reviews
2014

Defining the clinically meaningful difference in gait speed in persons with Parkinson disease.
Journal of neurologic physical therapy : JNPT
2014

Chronic Treatment With Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels But Not Alpha-Synuclein-Induced Neuronal Cell Loss
PLoS One
2014

An Eight-Year Clinic Experience With Clozapine Use in a Parkinson's Disease Clinic Setting
PLoS One
2014

Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.
The International journal of neuroscience
2013

Postural/Gait and cognitive function as predictors of driving performance in Parkinson's disease.
Journal of Parkinson's disease
2013

Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders
Neurodegenerative Diseases
2013

Efficient Determination of Purine Metabolites in Brain Tissue and Serum By High-Performance Liquid Chromatography With Electrochemical and Uv Detection
Biomedical Chromatography
2013

Driving Performance and Behaviors: a Comparison of Gender Differences in Parkinson's Disease
Traffic Injury Prevention
2013

Anti-Tau Antibodies: Hitting the Target
Neuron
2013

Advancing Research Towards Novel Therapeutic Approaches
Nature reviews. Neurology
2013

Quantitative normative gait data in a large cohort of ambulatory persons with Parkinson's disease.
PloS one
2012

Neurogenic Potential of Progenitor Cells Isolated From Postmortem Human Parkinsonian Brains
Brain Research
2012

Deep Brain Stimulation Response in Pathologically Confirmed Cases of Multiple System Atrophy
Parkinsonism & Related Disorders
2012

Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinson's Disease?
Journal of Neuropsychiatry and Clinical Neurosciences
2012

Interferon-Gamma Induces Progressive Nigrostriatal Degeneration and Basal Ganglia Calcification
Nature Neuroscience
2011

Research Interests

Dr. McFarland is an active member of the Center for Translational Research in Neurodegenerative Disease (CTRND) which aims to bring the bench closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and in particular the role of alpha-synuclein in cell toxicity and neurodegeneration. His current studies utilize both cellular and preclinical models to study genes and molecules that may affect brain pathology. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.